|
Sponsored Research and License Agreements (Details) (USD $)
|
1 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
Collaborations
|
Mar. 31, 2014
Collaborations
Development event
|
Mar. 31, 2014
Collaborations
Regulatory event
|
Mar. 31, 2014
Collaborations
Product launch event
|
Aug. 31, 2002
Daiichi
|
Mar. 31, 2014
Daiichi
|
Apr. 30, 2013
Daiichi
Milestone achieved
|
Jan. 31, 2012
Daiichi
Milestone achieved
|
Jul. 31, 2012
AstraZeneca worldwide license agreement JAK inhibitor
|
Jun. 30, 2012
AstraZeneca worldwide license agreement JAK inhibitor
|
Dec. 31, 2013
AstraZeneca worldwide license agreement JAK inhibitor
Development event
|
Jul. 31, 2012
BerGenBio
|
|
| Collaborations | ||||||||||||
| Maximum amount of contingent payments receivable | $ 152,300,000 | $ 61,200,000 | $ 53,600,000 | $ 37,500,000 | ||||||||
| Upfront fee received | 1,000,000 | |||||||||||
| Revenue recognized | 1,000,000 | 5,800,000 | ||||||||||
| Collaborative payment received | 1,400,000 | 750,000 | 500,000 | |||||||||
| Cumulative amount of payments earned under collaborative arrangement | $ 7,900,000 | |||||||||||
| Period of collaboration in research phase | 3 years | |||||||||||